Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial

Publikation

Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial

Wissenschaftlicher Artikel/Review - 01.06.2018

Wirsching H-G, Riklin C, Felsberg J, Roth P, Jones D T W, Pfister S, Rushing E J, Abrey L, Reifenberger G, Held L, von Deimling A, Ochsenbein A, von Moos R, Caparrotti F, Tabatabai G, Roelcke U, Hottinger A F, Jörger F, Schmid A, Plasswilm Ludwig, Schrimpf D, Mancao C, Capper D, Conen K, Hundsberger Thomas, Weller M

Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial

Abrey, L

Reifenberger, G

Held, L

von Deimling, A

Ochsenbein, A

Weller, M